Ralley Prentice, Emma Flanagan, Emily Wright, Winita Hardikar, Alyson Ross, Megan Burns, Lani Prideaux, William Connell, Miles Sparrow, Peter De Cruz, Mark Lust, Rimma Goldberg, Sara Vogrin, Tessa Greeve, Sally Bell
BACKGROUND: Despite reassuring clinical safety data, thrombocytosis, anemia, lymphopenia, and liver function derangements have been observed in infants born to women with inflammatory bowel disease (IBD) treated with thiopurines and biologics. We aimed to define the prevalence, course, associations, and clinical impact of hematological and biochemical abnormalities in such infants. METHODS: This multicenter prospective cohort study assessed clinical, hematologic, and biochemical outcomes of infants exposed to thiopurines or biologics in utero for management of maternal IBD...
February 8, 2024: Inflammatory Bowel Diseases